MA29890B1 - Composition a base d'herbes pour les troubles inflammatoires - Google Patents
Composition a base d'herbes pour les troubles inflammatoiresInfo
- Publication number
- MA29890B1 MA29890B1 MA30886A MA30886A MA29890B1 MA 29890 B1 MA29890 B1 MA 29890B1 MA 30886 A MA30886 A MA 30886A MA 30886 A MA30886 A MA 30886A MA 29890 B1 MA29890 B1 MA 29890B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- compositions
- relates
- naphtho
- octahydro
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 abstract 2
- 244000085223 Sphaeranthus indicus Species 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- XMPDAVDYIOMTLX-UHFFFAOYSA-N 3a-Hydroxy-5a,9-dimethyl-3-methylidene-4,5,6,7,8,9b-hexahydrobenzo[g][1]benzofuran-2-one Chemical compound C1CC2(C)CCCC(C)=C2C2OC(=O)C(=C)C21O XMPDAVDYIOMTLX-UHFFFAOYSA-N 0.000 abstract 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 abstract 1
- 230000021164 cell adhesion Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000005732 intercellular adhesion Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 210000005167 vascular cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
Abstract
L'INVENTION CONCERNE UNE COMPOSITION MÉDICINALE COMPRENANT UN EXTRAIT DE FLEUR ET DE FRUIT DE LA PLANTE SPHAERANTHUS INDICUS. L'EXTRAIT DE SPHAERANTHUS INDICUS RENFERME UN COMPOSÉ, 3A-HYDROXY-5A,9-DIMÉTHYL-3- MÉTHYLENE-3A,4,5,5A,6,7,8,9B-OCTAHYDRO-3H-NAPHTHO[1,2-B]FURAN-2-ONE (7- HYDROXY-4,1 1 (13)-EUDESMADIEN-12,6-OLIDE) (COMPOSÉ 1 ) EN TANT QUE MARQUEUR BIOACTIF. L'INVENTION CONCERNE ÉGALEMENT UNE COMPOSITION COMPRENANT 3A-HYDROXY-5A,9-DIMÉTHYL- 3-MÉTHYLENE-3A,4,5,5A,6,7,8,9B-OCTAHYDRO-3H-NAPHTHO[1,2-B]FURAN-2-ONE (COMPOSÉ 1 ) COMME INGRÉDIENT ACTIF. DE PLUS, L'INVENTION ENGLOBE DES MÉTHODES DE FABRICATION DESDITES COMPOSITIONS ET DES MÉTHODES D'ADMINISTRATION À U N SUJET DEVANT ÊTRE TRAITÉ POUR DES TROUBLES INFLAMMATOIRES. L'INVENTION PORTE ÉGALEMENT SUR L'ACTIVITÉ INHIBITRICE DE CES COMPOSITIONS À L'ÉGARD DU FACTEUR $G(A) DE NÉCROSE DES TUMEURS (TNF- A) ET DE L'INTERLEUKINE (IL-1, IL-6, IL-8). ELLE CONCERNE EN OUTRE L'INHIBITION PAR LESDITS COMPOSITIONS DE L'EXPRESSION DE LA MOLÉCULE 1 D'ADHÉSION INTERCELLULAIRE (ICAM-1 ), DE LA MOLÉCULE 1 D'ADHÉSION DES CELLULES VASCULAIRES (VCAM-1 ) ET DE LA SÉLECTINE E. CES COMPOSTIONS PEUVENT ÉVENTUELLEMENT CONTENIR AU MOINS UN AGENT ANTI-INFLAMMATOIRE OU PEUVENT ÊTRE UTILISÉES EN ASSOCIATION AVEC AU MOINS UN AGENT ANTI-INFLAMMATOIRE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1226MU2005 | 2005-09-30 | ||
| US73644305P | 2005-11-14 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29890B1 true MA29890B1 (fr) | 2008-10-03 |
Family
ID=37900158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30886A MA29890B1 (fr) | 2005-09-30 | 2008-04-29 | Composition a base d'herbes pour les troubles inflammatoires |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7635494B2 (fr) |
| EP (1) | EP1931366B1 (fr) |
| JP (1) | JP5331962B2 (fr) |
| AU (1) | AU2006296197B2 (fr) |
| CA (1) | CA2624049C (fr) |
| EA (1) | EA014070B1 (fr) |
| GE (1) | GEP20115332B (fr) |
| MA (1) | MA29890B1 (fr) |
| PL (1) | PL1931366T3 (fr) |
| WO (1) | WO2007036900A2 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981131B2 (en) * | 2007-07-27 | 2015-03-17 | Piramal Enterprises Limited | Tricyclic compounds for the treatment of inflammatory disorders |
| WO2009084032A2 (fr) * | 2007-12-03 | 2009-07-09 | Vedic Elements Private Limited | Formulation topique hydrophobe stable à base de plantes |
| WO2012014216A1 (fr) * | 2010-07-28 | 2012-02-02 | Laila Nutraceuticals | 7-hydroxyfrullanolide et ses analogues pour la prévention, la maîtrise et le traitement de troubles du métabolisme. |
| US10105347B2 (en) | 2009-02-02 | 2018-10-23 | Laila Nutraceuticals | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels |
| CN102292093B (zh) * | 2009-02-02 | 2015-01-28 | 莱拉营养食品有限公司 | 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物 |
| WO2011033524A2 (fr) * | 2009-08-04 | 2011-03-24 | Laila Nutraceuticals | Agents dérivés de ficus hispida pour l'amélioration du syndrome métabolique et de maladies associées |
| WO2011083397A1 (fr) * | 2010-01-05 | 2011-07-14 | Himalaya Global Holdings Limited | Composition phytothérapeutique pour les troubles de la peau |
| PH12013500451A1 (en) * | 2010-09-11 | 2013-05-20 | Laila Nutraceuticals | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels |
| US8263579B2 (en) * | 2011-01-24 | 2012-09-11 | Piramal Healthcare Limited | Anti-inflammatory compounds |
| TW201427677A (zh) * | 2012-10-23 | 2014-07-16 | Piramal Entpr Ltd | 用於預防及治療腫瘤壞死因子-α媒介疾病中藥組合物 |
| EP3313384A4 (fr) | 2015-06-23 | 2019-04-03 | Nobilis Therapeutics, Inc. | Modulation immunitaire thérapeutique à l'aide de compositions de gaz noble |
| WO2017203540A1 (fr) * | 2016-05-21 | 2017-11-30 | Laila Impex | Compléments alimentaires et compositions permettant d'améliorer les performances physiques et les niveaux d'énergie |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646687A (en) * | 1994-12-29 | 1997-07-08 | Lucent Technologies Inc. | Temporally-pipelined predictive encoder/decoder circuit and method |
| US6204523B1 (en) * | 1998-11-06 | 2001-03-20 | Lumileds Lighting, U.S., Llc | High stability optical encapsulation and packaging for light-emitting diodes in the green, blue, and near UV range |
| US6686676B2 (en) * | 2001-04-30 | 2004-02-03 | General Electric Company | UV reflectors and UV-based light sources having reduced UV radiation leakage incorporating the same |
| US6989412B2 (en) * | 2001-06-06 | 2006-01-24 | Henkel Corporation | Epoxy molding compounds containing phosphor and process for preparing such compositions |
| US6841647B2 (en) * | 2001-11-06 | 2005-01-11 | National Starch And Chemical Investment Holding Corporation | Fluid resistant silicone encapsulant |
| US7160972B2 (en) * | 2003-02-19 | 2007-01-09 | Nusil Technology Llc | Optically clear high temperature resistant silicone polymers of high refractive index |
| US7261441B2 (en) * | 2004-02-27 | 2007-08-28 | Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. | LED device and method for directing LED light |
| WO2006016228A2 (fr) * | 2004-08-02 | 2006-02-16 | Prashanth Kumar V | Alkaloide peptide cytotoxique et compositions pharmaceutiques pour le traitement des maladies neoplastiques |
| US7229934B2 (en) * | 2004-10-18 | 2007-06-12 | International Business Machines Corporation | Porous organosilicates with improved mechanical properties |
-
2006
- 2006-09-28 AU AU2006296197A patent/AU2006296197B2/en not_active Ceased
- 2006-09-28 PL PL06809434T patent/PL1931366T3/pl unknown
- 2006-09-28 WO PCT/IB2006/053540 patent/WO2007036900A2/fr not_active Ceased
- 2006-09-28 CA CA2624049A patent/CA2624049C/fr active Active
- 2006-09-28 GE GEAP200610647A patent/GEP20115332B/en unknown
- 2006-09-28 EA EA200800850A patent/EA014070B1/ru active IP Right Revival
- 2006-09-28 JP JP2008532961A patent/JP5331962B2/ja not_active Expired - Fee Related
- 2006-09-28 EP EP06809434.1A patent/EP1931366B1/fr active Active
-
2008
- 2008-03-28 US US12/079,853 patent/US7635494B2/en active Active
- 2008-04-29 MA MA30886A patent/MA29890B1/fr unknown
-
2009
- 2009-07-09 US US12/500,057 patent/US8206756B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2624049A1 (fr) | 2007-04-05 |
| WO2007036900A2 (fr) | 2007-04-05 |
| HK1112418A1 (en) | 2008-09-05 |
| CA2624049C (fr) | 2016-01-12 |
| AU2006296197A2 (en) | 2008-06-05 |
| AU2006296197A1 (en) | 2007-04-05 |
| US7635494B2 (en) | 2009-12-22 |
| US20090269427A1 (en) | 2009-10-29 |
| JP5331962B2 (ja) | 2013-10-30 |
| JP2009510051A (ja) | 2009-03-12 |
| EA200800850A1 (ru) | 2008-10-30 |
| US20080254157A1 (en) | 2008-10-16 |
| AU2006296197B2 (en) | 2012-08-09 |
| PL1931366T3 (pl) | 2013-11-29 |
| US8206756B2 (en) | 2012-06-26 |
| GEP20115332B (en) | 2011-11-25 |
| WO2007036900A3 (fr) | 2007-08-02 |
| EP1931366B1 (fr) | 2013-05-29 |
| EA014070B1 (ru) | 2010-08-30 |
| EP1931366A2 (fr) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30342B1 (fr) | Nouvelles compositions pour des troubles capillaires et procede de preparation de celles-ci | |
| MA29630B1 (fr) | Ingredient pharmaceutique actif du cannabinoide pour des formes de dosage ameliorees | |
| FR2393531A1 (fr) | Compositions fongicides pour l'agriculture a base de derives de 4-aminoquinazoline | |
| WO2005000241A3 (fr) | Compositions et procedes pour administration topique | |
| EA200800850A1 (ru) | Растительная композиция для воспалительных нарушений | |
| MA27125A1 (fr) | Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose | |
| WO2006119389A3 (fr) | Preparations de quinine | |
| Aggarwal et al. | Ocimum tenuiflorum–A Medicinal Plants with its versatile uses | |
| Hakobjanyan et al. | Medicinal potential of Thuja occidentalis and its essential oil | |
| Sheneni et al. | Anti-hyperlipidemic effect of Vitex doniana ethanol extract in poloxamer induced hyperlipidemia | |
| CA2441826A1 (fr) | Compositions fongicides a base de derive de pyridylmethylbenzamide et de propamocarbe | |
| ES2426174T8 (es) | Composición herbácea para trastornos inflamatorios | |
| Bharskar | Review on phytochemistry and pharmacological aspects of Pedalium murex Linn | |
| Hal et al. | Biological Review on different species belonging to Zygophyllum genus | |
| AR037334A1 (es) | Composicion fungicida que comprende pirimetanil y al menos un derivado de acido fosforoso y utilizacion de esta composicion para la lucha contra las enfermedades de las plantas | |
| Mohamed et al. | Promising selective MAO-B inhibition by sesamin, a lignan from Zanthoxylum flavum stems | |
| Bhattacharya et al. | In vitro regeneration of some lesser known medicinal Zingibers: a review | |
| Arora et al. | Mesua Ferrea: an ethnobotanically important plant | |
| Mohebbati et al. | Hypotensive effect of hydroalcoholic Ziziphus jujuba extract on normotensive rats | |
| Ahmed et al. | Effects of Silymarin against Hepatic and Renal Toxicity Induced by Methotrexate in Rats. | |
| WO2007014379A3 (fr) | Extrait lipidique provenant de lepidium meynii et effet de celui-ci sur la libido | |
| Isla et al. | Fabiana punensis SC Arroyo, F. bryoides Phil., F. densa Remy, F. patagonica Speg. | |
| Erjaee et al. | Evaluation of the Anti-inflammatory and Antioxidant Parameters of Aqueous and Ethanolic Extracts of Roman chamomile in mice | |
| Kalam et al. | Bishari booti (Aerva lanata (L.) Juss. Ex Schult): Ethanomedicinal importance of a valuable plant from Mother Nature | |
| WO2007042983A3 (fr) | Utilisation de fluridone comme agent anti-inflammatoire |